Skip to main content
Retour
ARGX logo

argenx SE

Qualité des données : 100%
Survendu
ARGX
NASDAQ Healthcare Biotechnology
677,50 €
▼ 4,35 € (-0,64%)
Cap. Boursière : 41,93B
Également cotée sous ARGNF OTC
Fourchette du Jour
666,79 € 677,85 €
Fourchette 52 Semaines
510,06 € 934,62 €
Volume
256 342
Moyenne 50J / 200J
791,83 € / 749,96 €
Clôture Précédente
681,85 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 32,4 0,3
P/B 5,7 2,9
ROE % 20,2 3,7
Net Margin % 31,1 3,8
Rev Growth 5Y % 70,1 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
1 026,71 € +51.5%
Low: 858,00 € High: 1 317,00 €
P/E Prévisionnel
25,8
BPA Prévisionnel
26,47 €
Croissance BPA (est.)
+0,0%
CA Est.
6 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 59,47 €
51,80 € – 67,36 €
11 B 5
FY2029 51,95 €
45,25 € – 58,84 €
9,8 B 11
FY2028 45,30 €
39,46 € – 51,32 €
8,5 B 9

Points Clés

Revenue grew 70,11% annually over 5 years — strong growth
Earnings grew 55,58% over the past year
ROE of 20,22% indicates high profitability
Net margin of 31,12% shows strong profitability
Debt/Equity of 0,01 — conservative balance sheet
Generating 844,30M in free cash flow

Croissance

Revenue Growth (5Y)
70,11%
Revenue (1Y)90,12%
Earnings (1Y)55,58%
FCF Growth (3Y)N/A

Qualité

Return on Equity
20,22%
ROIC9,85%
Net Margin31,12%
Op. Margin23,35%

Sécurité

Debt / Equity
0,01
Current Ratio5,23
Interest Coverage237,50

Valorisation

P/E Ratio
32,35
P/B Ratio5,73
EV/EBITDA39,61
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 90,12% Revenue Growth (3Y) 84,27%
Earnings Growth (1Y) 55,58% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 70,11% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4,16B Net Income (TTM) 1,30B
ROE 20,22% ROA 14,93%
Gross Margin 89,14% Operating Margin 23,35%
Net Margin 31,12% Free Cash Flow (TTM) 844,30M
ROIC 9,85% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 5,23
Interest Coverage 237,50 Dividend Yield 0,00%
Valuation
P/E Ratio 32,35 P/B Ratio 5,73
P/S Ratio 10,07 PEG Ratio 0,77
EV/EBITDA 39,61 Dividend Yield 0,00%
Market Cap 41,93B Enterprise Value 38,52B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,16B 2,19B 1,23B 410,75M 497,28M
Net Income 1,30B 833,04M -295,05M -709,59M -407,63M
EPS (Diluted) 19,63 12,78 -5,16 -13,05 -7,99
Gross Profit 3,71B 1,96B 1,11B 381,32M 497,28M
Operating Income 972,46M -21,65M -425,05M -720,34M -348,75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,68B 6,20B 4,54B 3,13B 2,85B
Total Liabilities 1,36B 704,24M 444,95M 320,56M 316,05M
Shareholders' Equity 7,32B 5,50B 4,10B 2,81B 2,53B
Total Debt 83,49M 39,05M 20,00M 12,43M 11,47M
Cash & Equivalents 3,49B 1,50B 2,05B 800,74M 1,33B
Current Assets 6,90B 4,88B 4,12B 2,77B 2,54B
Current Liabilities 1,32B 669,92M 422,99M 302,28M 301,24M

Scores de Stratégies

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
#41 of 157
74
Custom Full Throttle
#13 of 146
69
Custom Lower Risk
#39 of 140
52

Activité Récente

Entré Growth Investing (Philip Fisher)
Mar 24, 2026
Entré Full Throttle
Mar 24, 2026
Entré Lower Risk
Mar 24, 2026